We showed the potential for the TP53 mutated ctDNA to identify NHL patients with an expected poor or good response after CAR T cell therapy, and our results suggest that TP53-mutated ctDNA within the first trimester can predict disease progression and the PFS of NHL patients receiving CAR T cell therapy and that ctDNA levels can also reflect the change in tumor burden. This evidence concerns the gene TP53 and neoplasm.